ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
"We are delighted to have the opportunity to host an oral mucositis symposium and to present MuGard information and clinical data to such a broad and prestigious audience at this year's MASCC conference," said Jeffrey Davis, President and CEO of Access Pharmaceuticals, Inc. He continued, "As we continue our efforts to commercially launch MuGard in North America, our presence at the MASCC conference demonstrates our strategic focus on raising the awareness of the product's important role in the management of oral mucositis."
MASCC, or the Multinational Association of Supportive Care in Cancer, is an international organization dedicated to the research and education in all aspects of supportive care for patients with cancer. It joined forces with the International Society of Oral Oncology (ISOO) in 1998, and its members represent over sixty countries. The MASCC/ISOO membership includes oncology medical, surgical, and radiology physicians, nurses, dentists, dental hygienists, pharmacists and representatives from industry and non-profit sectors. Symposia are convened annually to share the most recent research in supportive care from throughout the world.
Access Pharma recently announced it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities. MuGard has been launched in the UK, Germany, Italy, Sweden, Norway and Greece through its European partner, SpePharm. Additionally, JCOM, Inc., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration (KFDA) for MuGard. The Company plans on commercially launching MuGard in Korea and North America later this year.
Rare genetic mutations in healthy women may be key to breast cancer origins